11 research outputs found
Coronary plaque redistribution after stent implantation is determined by lipid composition: A NIRS-IVUS analysis
Background: The composition of plaque impacts the results of stenting. The following study evaluated plaque redistribution related to stent implantation using combined near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS) imaging.
Methods: The present study included 49 patients (mean age 66 ± 11 years, 75% males) presenting with non-ST elevation myocardial infarction (8%), unstable angina (49%) and stable coronary artery disease (43%). The following parameters were analyzed: mean plaque volume (MPV, mm3), plaque burden (PB, %), remodeling index (RI), and maximal lipid core burden index in a 4 mm segment (maxLCBI4mm). High-lipid burden lesions (HLB) were defined as by maxLCBI4mm > 265 with positive RI. Otherwise plaques were defined as low-lipid burden lesions (LLB). Measurements were done in the target lesion and in 4 mm edges of the stent before and after stent implantation.
Results: MPV and maxLCBI4mm decreased in both HLB (MPV 144.70 [80.47, 274.25] vs. 97.60 [56.82, 223.45]; maxLCBI4mm: 564.11 ± 166.82 vs. 258.11 ± 234.24, p = 0.004) and LLB (MPV: 124.50 [68.00, 186.20] vs. 101.10 [67.87, 165.95]; maxLCBI4mm: 339.07 ± 268.22 vs. 124.60 ± 160.96, p < 0.001), but MPV decrease was greater in HLB (28.00 [22.60, 57.10] vs. 13.50 [1.50, 28.84], p = 0.019). Only at the proximal stent edge of LLB, maxLCBI4mm decreased (34 [0, 207] vs. 0 [0, 45], p = 0.049) and plaque burden increased (45.48 [40.34, 51.55] vs. 51.75 [47.48, 55.76], p = 0.030).
Conclusions: NIRS-IVUS defined HLB characterized more significant decreases in plaque volume by stenting. Plaque redistribution to the proximal edge of the implanted stent occurred only in LLB
Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study
Aims: To investigate if recent technical and procedural developments in percutaneous coronary intervention (PCI) significantly influence outcomes in appropriately selected patients with three-vessel (3VD) coronary artery disease. Methods and results: The SYNTAX II study is a multicenter, all-comers, open-label, single arm study that investigated the impact of a contemporary PCI strategy on clinical outcomes in patients with 3VD in 22 centres from four European countries. The SYNTAX-II strategy includes: heart team decision-making utilizing the SYNTAX Score II (a clinical tool combining anatomical and clinical factors), coronary physiology guided revascularisation, implantation of thin strut bio-resorbable-polymer drug-eluting stents, intravascular ultrasound (IVUS) guided stent implantation, contemporary chronic total occlusion revascularisation techniques and guideline-directed medical therapy. The rate of major adverse cardiac and cerebrovascular events (MACCE [composite of all-cause death, cerebrovascular event, any myocardial infarction and any revascularisation]) at one year was compared to a predefined PCI cohort from the original SYNTAX-I trial selected on the basis of equipoise 4-year mortality between CABG and PCI. As an exploratory endpoint, comparisons were made with the historical CABG cohort of the original SYNTAX-I trial. Overall 708 patients were screened and discussed within the heart team; 454 patients were deemed appropriate to undergo PCI. At one year, the SYNTAX-II strategy was superior to the equipoise-derived SYNTAX-I PCI cohort (MACCE SYNTAX-II 10.6% vs. SYNTAX-I 17.4%; HR 0.58, 95% CI 0.39-0.85, P= 0.006). This difference was driven by a significant reduction in the incidence of MI (HR 0.27, 95% CI 0.11-0.70, P= 0.007) and revascularisation (HR 0.57, 95% CI 0.37-0.9, P = 0.015). Rates of all-cause death (HR 0.69, 95% CI 0.27-1.73, P = 0.43) and stroke (HR 0.69, 95% CI 0.10-4.89, P = 0.71) were similar. The rate of definite stent thrombosis was significantly lower in SYNTAX-II (HR 0.26, 95% CI 0.07-0.97, P = 0.045). Conclusion: At one year, clinical outcomes with the SYNTAX-II strategy were associated with improved clinical results compared to the PCI performed in comparable patients from the original SYNTAX-I trial. Longer term follow-up is awaited and a randomized clinical trial with contemporary CABG is warranted
TCT-745 Feasibility and outcomes of transcatheter aortic valve implantation in high-risk patients with stenotic bicuspid aortic valves
TCT-575 Comparison of clinical outcomes and safety of first and second-generation DES in women and men [Katowice-Zabrze Registry on first and second generation DES]
TCT-443 Multiplug Paravalvular Leak Closure Using Amplatzer Vascular Plug III – Prospective Registry (Wizzard I)
TCT-443 Multiplug Paravalvular Leak Closure Using Amplatzer Vascular Plug III – Prospective Registry (Wizzard I)
Age-Related 2-Year Mortality After Transcatheter Aortic Valve Replacement: the Young TAVR Registry
Objective: To comparatively assess the natural history of patients of different ages undergoing
transcatheter aortic valve replacement (TAVR).
Patients and Methods: For this study, we used the YOUNG TAVR, an international, multicenter
registry investigating mortality trends up to 2 years in patients with aortic valve stenosis treated by
TAVR, classified according to 3 prespecified age groups: 75 years or younger (n¼179), 76 to 86 years
(n¼602), and older than 86 years (n¼221). A total of 1002 patients undergoing TAVR were included.
Demographic, clinical, and outcome data in the youngest group were compared with those of patients
76 to 86 years and older than 86 years. Patients were followed up for up to 2 years.
Results: Compared with patients 75 years or younger (reference group), patients aged 76 to 86 years
and older than 86 years had nonsignificantly different 30-day mortality (odds ratio, 0.76; 95% CI,
0.41-1.38; P¼.37 and odds ratio, 1.27; 95% CI, 0.62-2.60; P¼.51, respectively) and 1-year mortality
(hazard ratio (HR), 0.72; 95% CI, 0.48-1.09; P¼.12 and HR, 1.11; 95% CI, 0.88-1.40; P¼.34,
respectively). Mortality at 2 years was significantly lower among patients aged 76 to 86 years (HR,
0.62; 95% CI, 0.42-0.90; P¼.01) but not among the older group (HR, 1.06; 95% CI, 0.68-1.67; P¼.79).
The Society of Thoracic Surgeons 30-day mortality score was lower in younger patients who, however,
had a significantly higher prevalence of chronic obstructive pulmonary disease (P¼.005 vs the intermediate
group and P¼.02 vs the older group) and bicuspid aortic valves (P¼.02 vs both older
groups), larger left ventricles, and lower ejection fractions.
Conclusion: In the present registry, mortality at 2 years after TAVR among patients 75 years or
younger was higher compared with that of patients aged 75 to 86 years and was not markedly different
from that of patients older than 86 years. The findings are attributable at least in part to a greater
burden of comorbidities in the younger age group that are not entirely captured by current risk
assessment tools
Transcatheter Aortic Valve Implantation for Pure Severe Native Aortic Valve Regurgitation
ObjectivesThis study sought to collect data and evaluate the anecdotal use of transcatheter aortic valve implantation (TAVI) in pure native aortic valve regurgitation (NAVR) for patients who were deemed surgically inoperableBackgroundData and experience with TAVI in the treatment of patients with pure severe NAVR are limited.MethodsData on baseline patient characteristics, device and procedure parameters, echocardiographic parameters, and outcomes up to July 2012 were collected retrospectively from 14 centers that have performed TAVI for NAVR.ResultsA total of 43 patients underwent TAVI with the CoreValve prosthesis (Medtronic, Minneapolis, Minnesota) at 14 centers (mean age, 75.3 ± 8.8 years; 53% female; mean logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation), 26.9 ± 17.9%; and mean Society of Thoracic Surgeons score, 10.2 ± 5.3%). All patients had severe NAVR on echocardiography without aortic stenosis and 17 patients (39.5%) had the degree of aortic valvular calcification documented on CT or echocardiography. Vascular access was transfemoral (n = 35), subclavian (n = 4), direct aortic (n = 3), and carotid (n = 1). Implantation of a TAVI was performed in 42 patients (97.7%), and 8 patients (18.6%) required a second valve during the index procedure for residual aortic regurgitation. In all patients requiring second valves, valvular calcification was absent (p = 0.014). Post-procedure aortic regurgitation grade I or lower was present in 34 patients (79.1%). At 30 days, the major stroke incidence was 4.7%, and the all-cause mortality rate was 9.3%. At 12 months, the all-cause mortality rate was 21.4% (6 of 28 patients).ConclusionsThis registry analysis demonstrates the feasibility and potential procedure difficulties when using TAVI for severe NAVR. Acceptable results may be achieved in carefully selected patients who are deemed too high risk for conventional surgery, but the possibility of requiring 2 valves and leaving residual aortic regurgitation remain important considerations